SAR449028

Unknown / undisclosed

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

—no registered trials

Evidence outlook

No clinical trials on ClinicalTrials.gov

No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.

No registered studies found. Not yet ingested, or none registered.

Competitive landscape

4 other tracked programmes target this mechanism.

This drug's own stage for Chronic Spontaneous Urticaria: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
SAR449028: this drugStage not on recordUndisclosedKITnot yet gradedNo reviewed efficacy summary in this indication
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Omalizumab (Xolair)ApprovedMonoclonal antibodyIgE (immunoglobulin E), IgEPartial signal
NCT01287117: Change From Baseline to Week 12 in the Weekly Itch Severity Score (Baseline to Week 12): Placebo -3.63 Units on a scale (Standard Deviation 5.22) | Omalizumab 75 mg -6.46 Units on a scale (Standard Deviation 6.14) | Omalizumab 150 mg -6.66 Units on a scale (Standard Deviation 6.28) | Omalizumab 300 mg -9.4 Units on a scale (Standard Deviation 5.73)
NCT01292473: Change in weekly itch severity score at week 12 vs placebo (-5.14): omalizumab 75 mg -5.87, difference -0.69 (95% CI -2.54 to 1.16), p=0.4637; 150 mg -8.14, difference -3.04 (95% CI -4.85 to -1.24), p=0.0011; 300 mg -9.77, difference -4.81 (95% CI -6.49 to -3.13), p<0.0001 (CT.gov posted results).
RemibrutinibApprovedSmall moleculeBruton's tyrosine kinase (BTK)Reliable signalNo reviewed efficacy summary in this indication
BarzolvolimabPhase 3Monoclonal antibodyKITPartial signal
NCT06445023: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22).
NCT06455202: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22).
Bezuclastinib
Phase 3(overall)
Small moleculeKIT
not yet graded(overall)
No reviewed efficacy summary in this indication
Velzatinib
Phase 3(overall)
Small moleculeKIT
not yet graded(overall)
No reviewed efficacy summary in this indication
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
HRS-3095Phase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
BriquilimabPhase 1/2Monoclonal antibodyKITnot yet gradedNo reviewed efficacy summary in this indication
Girocitinib
—(overall)
Small moleculeTYK2/JAK1Reliable signalNo reviewed efficacy summary in this indication
SHR-3095
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.